Literature DB >> 8731505

Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.

R A Reisfeld1, S D Gillies.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8731505     DOI： 10.1002/(SICI)1098-2825(1996)10:3<160::AID-JCLA9>3.0.CO;2-F

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN： 0887-8013            Impact factor:   2.352


× No keyword cloud information.
  11 in total

1.  Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins.

Authors:  J Gan; K Kendra; M Ricci; J A Hank; S D Gillies; P M Sondel
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 2.  Cytokines in the Treatment of Cancer.

Authors:  Kevin C Conlon; Milos D Miljkovic; Thomas A Waldmann
Journal:  J Interferon Cytokine Res       Date:  2018-06-11       Impact factor: 2.607

3.  High efficient mammalian expression and secretion of a functional humanized single-chain Fv/human interleukin-2 molecules.

Authors:  Yue-Chun Shen; Xue-Hao Wang; Xiao-Ming Wang; Zao-Lai Chen; Xi-Ping Shen; Chao-Chen Zhao; Jun Li
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

Review 4.  The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.

Authors:  Thomas A Waldmann
Journal:  Cancer Immunol Res       Date:  2015-03       Impact factor: 11.151

Review 5.  Protein kinase C in IL-2 signal transduction.

Authors:  Y Lu; J P Durkin
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

6.  Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells.

Authors:  Cornelia Hutmacher; Nicolás Gonzalo Núñez; Anna Rita Liuzzi; Burkhard Becher; Dario Neri
Journal:  Cancer Immunol Res       Date:  2019-02-19       Impact factor: 11.151

7.  Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.

Authors:  Mark R Albertini; Richard K Yang; Erik A Ranheim; Jacquelyn A Hank; Cindy L Zuleger; Sharon Weber; Heather Neuman; Greg Hartig; Tracey Weigel; David Mahvi; Mary Beth Henry; Renae Quale; Thomas McFarland; Jacek Gan; Lakeesha Carmichael; KyungMann Kim; Hans Loibner; Stephen D Gillies; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2018-08-03       Impact factor: 6.968

8.  Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2.

Authors:  Richard K Yang; Igor B Kuznetsov; Javed Khan; Paul M Sondel; Erik A Ranheim; Jun S Wei; Sivasish Sindiri; Berkley E Gryder; Vineela Gangalapudi; Young K Song; Viharkumar Patel; Jacquelyn A Hank; Cindy Zuleger; Amy K Erbe; Zachary S Morris; Renae Quale; KyungMann Kim; Mark R Albertini
Journal:  Clin Cancer Res       Date:  2020-03-09       Impact factor: 12.531

9.  Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.

Authors:  Jacquelyn A Hank; Jacek Gan; Hyunji Ryu; Amy Ostendorf; Michael C Stauder; Adam Sternberg; Mark Albertini; Kin-Ming Lo; Stephen D Gillies; Jens Eickhoff; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

10.  A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.

Authors:  Kaci L Osenga; Jacquelyn A Hank; Mark R Albertini; Jacek Gan; Adam G Sternberg; Jens Eickhoff; Robert C Seeger; Katherine K Matthay; C Patrick Reynolds; Clare Twist; Mark Krailo; Peter C Adamson; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.